亚洲 · 区域市场 · The Financial Express
Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected in 2028
详细摘要
Biocon wins US FDA approval for cancer biosimilar Pebrilzo, strengthening its oncology portfolio ahead of a 2028 launch; learn more.
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.financialexpress.com)




